Introduction
============

Although acute pain is predictable after operations, the management of postoperative pain is indeed a difficult challenge for anesthesiologists. Despite the increased knowledge about nociception and advance in pharmacology, over 80% of surgical patients are reported to experience moderate pain and 31-37% of patients experience severe or extreme pain \[[@B1],[@B2]\]. Inadequately controlled pain after surgery may result in many unwanted consequences, along with patient discomfort and suffering, increased risk of myocardial ischemia, impaired rehabilitation, impaired wound healing, delayed gastrointestinal motility, immune alterations, pulmonary complications due to poor respiratory effort, and increased risk of thromboembolism due to immobilization \[[@B3],[@B4],[@B5],[@B6],[@B7],[@B8]\].

Traditionally, opioid-based analgesia has been the primary modality for most of the severe postoperative pain management. But, the use of opioids, especially when monomodal, have been associated with risks of complications and adverse effects \[[@B9],[@B10]\]. The primary use of opioids are associated with respiratory depression, sedation, drowsiness, pruritus, skin rash, urinary retention, delayed gastrointestinal motility, and postoperative vomiting and nausea \[[@B11]\]. Furthermore, within the first 12 hours post-operation, over sedation related to postoperative analgesic use was observed in 72.7% of patients, which may have led to dangerous conditions \[[@B12]\].

Considering the conditions associated with opioid-based analgesia, the concept of \"multimodal analgesia\" has been proposed in the early 1990s to overcome the opioid induced adverse effects and at the same time, to achieve sufficient analgesia \[[@B9],[@B10]\]. Based on the ladder of therapy for cancer pain, the proposed ladder of therapy for multimodal postoperative pain management is shown in [Fig. 1](#F1){ref-type="fig"} \[[@B13]\]. The rationale of this concept is through additive or synergetic effects between analgesics of different mechanism, will allow optimal level of analgesia. This will allow a reduction in any individual analgesic dose that may decrease the occurrence of adverse effects associated with overdose from a single analgesic \[[@B14]\]. Recently, the American Society of Anesthesiologists Task Force on Acute Pain Management has recommended utilization of multimodal analgesia management therapy whenever possible \[[@B4]\]. These include 1) Regional/central nerve blocks with local anesthetics; 2) \"Around-the-clock\" regimen of non-opioid analgesics consisting of nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 selective NSAIDs (COXIBs), and acetaminophen unless they are contraindicated.

Thus, according to the new guidelines proposed at 2012, as a part of the multimodal analgesia, the use of acetaminophen, NSAIDs, and COXIBs should always be considered for acute postoperative pain management. Although these agents may be insufficient as a single regimen to treat severe pain, they may be acceptable augmentation to opioids and may result a substantial decrease in opioid requirements, which is associated with the decrease or possible avoidance of opioid related side effects \[[@B9],[@B14],[@B15],[@B16],[@B17]\]. The utility of non-opioid analgesics are very broad, as they can be used preoperatively as a part of preemptive and preventive regimen, intraoperative usage to block surgical nociception along with opioids and regional anesthesia, and for postoperative pain control to increase the efficacy of opioids and reduce its side effects \[[@B18],[@B19]\].

The non-opioid analgesics can be delivered in various routes including oral, rectal, intravenous, and recently intranasal formulation. And diverse number of NSAIDs, COXIBs, and other miscellaneous drugs (in example; nefopam, gabapentin, ketamine) have been studied and utilized for a part of multimodal analgesia. In the present topic, we will focus on the clinical uses, dosing, opioid-sparing effects, safety, and efficacy of the intravenous acetaminophen and intravenous ibuprofen.

Intravenous Acetaminophen
=========================

Acetaminophen (or paracetamol) was first used clinically in 1887 and has been widely marketed from the 1950s \[[@B20]\]. Since then, it has become one of the most frequently used and ordered antipyretic and analgesic drug, secondary to its high therapeutic index \[[@B20],[@B21]\]. Acetaminophen has analgesic and antipyretic effects, but unlike the NSAIDs, it does not have peripheral anti-inflammatory effects \[[@B22]\]. Furthermore, it does not affect the platelet function, therefore, making it useful during any time of operation \[[@B23]\].

The analgesic mechanism of acetaminophen is not completely understood. It has been known to be a centrally acting inhibitor of the prostaglandins via the cyclooxygenase (COX) pathway \[[@B17],[@B24]\]. Acetaminophen has shown to rapidly enter the central nervous system and most of the actions involved in analgesia acts in the central nervous system \[[@B25],[@B26]\]. In vitro, acetaminophen demonstrated a 4.4 times receptor selectiveness to COX-2, compared with COX-1 \[[@B27]\]. It is known to act as nitric oxide pathway inhibitor through substance P or N-methyl-D-aspartate \[[@B28],[@B29]\], and strengthen the descending serotonergic inhibitory pathways \[[@B30]\]. Recently, active metabolites of acetaminophen presented to have effect on the cannabinoid receptors \[[@B31],[@B32],[@B33]\]. Acetaminophen, via this process, is de-acetylated in the spinal cord and then brain to *p*-aminophenol, and through conjugation with arachidonic acid, where it forms N-arachidonoylphenolamine (AM404). AM404, a powerful facilitator of the transient receptor potential vanilloid subtype 1 receptor (TRPV1) and a ligand of cannabinoid type 1 receptors, inhibits the cellular anandamide uptake, resulting in an elevated level of endogenous cannabinoids (encannabinoids). The cellular anandamide uptake culminates in the triggering of nociceptors that is inhibited following acetaminophen administration. In animal studies, AM404 has shown to produce anti-nociception by activating TRPV1 in the brain \[[@B33]\].

Acetaminophen has been available in the market as oral and suppository form for many decades, and the intravenous form has been recently introduced and received its approval in Europe at 2002 and in United States at 2010. Currently, it has received approval for clinical use in approximately 80 countries around the world \[[@B17]\]. It has been available in Korea from 2007 (Perfalgan®), but recently the supply has been stopped (2012) due to supplier marketing policies. The pro-drug form of intravenous acetaminophen, propacetamol, which is rapidly hydrolyzed in blood to acetaminophen, has been available in Korea since 1995 and is currently in supply by various companies. Introduction of intravenous acetaminophen has provided benefits to the periand postoperative pain management compared to the previous oral or rectal formulations. It is a convenient, fast-acting, safe analgesic which is readily usable at the perioperative period, allowing the early initiation of multimodal analgesia possible \[[@B14],[@B34]\]. The intravenous route also enables the delivery of this drug during the immediate postoperative period, when medication via oral or rectal route is difficult or impossible.

After intravenous administration of acetaminophen, a rapid and high plasma concentration is achieved within 5 minutes, with the initiation of pain relief also occurring within five minutes \[[@B34]\]. Peak plasma concentration occurs at the completion of a 15 minute administration, and that is on the order of 30 minutes faster than oral formulation \[[@B34],[@B35]\]. Intravenously administered acetaminophen rapidly crosses the blood-brain barrier. Because of its high lipid solubility and low protein binding properties, acetaminophen is readily detectable in the cerebrospinal fluid (CSF) within minutes after intravenous delivery, and the concentrations in the CSF have been demonstrated to be directly proportional to plasma levels after intravenous doses between 500 mg to 2,000 mg \[[@B14],[@B26],[@B36],[@B37]\]. Therefore, the analgesic profiles are parallel to the concentration-time curve in the CSF and the concentration-time curve in the plasma \[[@B36]\]. After standard infusion of 1 g of acetaminophen for 15 minutes in the adult, the maximum plasma concentration (C~max~) was reported to be 29.9 mg/L immediately after infusion, 26.0 ± 7.7 mg/L 4 hours after infusion, and 28.4 ± 21.2 mg/L 8 hours after infusion, which is approximately 70-75% higher than the C~max~ of an equivalent oral dose. Indeed, the intravenous administration resulted in significantly increased concentration in the central nervous system compared to oral delivery (C~max~ = 5.94 vs. 3.72 mg/L). The time to reach maximum concentration (T~max~) for the intravenous acetaminophen after 15 minute infusion was approximately 30 minutes faster compared with oral formulation \[[@B11],[@B17],[@B38]\]. These differences in the pharmacokinetics of intravenous acetaminophen compared with the oral form arise from the fact that the intravenous form does not go through the first pass effect which the oral form does, which is a well known phenomenon with intravenous vs. oral drugs. The main pharmacokinetic parameters of intravenous acetaminophen is shown in [Table 1](#T1){ref-type="table"}. The metabolism and excretion of acetaminophen did not demonstrate significant difference between the routes of administration. In the liver, acetaminophen is metabolized by sulfation, oxidation, and glucuronidation. In the oxidative pathway, cytochrome P450 isoenzyme CYP2E1 produces N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is then conjugated with intracellular glutathione and excreted in the urine as 3\'-\[S-cysteinyl\] acetaminophen, 3\'-S-metyhlacetaminophen, and acetaminophen mercapturate. After acute acetaminophen overdose or heavy alcohol consumption, glutathione storage can be depleted, and NAPQI may cause hepatotoxicity \[[@B39],[@B40],[@B41]\].

The dose of intravenous acetaminophen in adolescents and adults is 1 g every 4-6 hours, with a maximum daily dose of 4 grams. In children of 2 years of age and older, and adolescents, and adults weighing less than 50 kg, 15 mg/kg should be administered at the same interval. Under 2 years of age, children and infants should receive no more than 10 mg/kg, and neonates and premature infants probably on 7.5 mg/kg, although exact dosing has not been established. The elimination half-life is 2-3 hours, and the duration of analgesic effect is approximately 4-6 hours and it may be prolonged in infants, neonates, and patients with renal impairment \[[@B42],[@B43]\].

Numerous studies demonstrating the safety and efficacy of intravenous acetaminophen have been conducted since its introduction. Recently, several detailed articles reviewing the previous studies have been published. In 2011, Macario and Royal reviewed the previously published clinical trials of the efficacy and safety of perioperative intravenous acetaminophen for postoperative pain control that were randomized and placebo-controlled. Sixteen articles involving 1,464 patients were reviewed. The investigators discovered that patients had lower pain scores in 12 of 14 trials and postoperative opioid use was reduced in 10 of 14 trials when receiving perioperative acetaminophen \[[@B44]\]. Another systematic review of 36 studies involving 3,896 patients found that 37% of patients receiving a single intravenous dose of paracetamol (acetaminophen) or propacetamol had experienced a minimum of 50% pain relief for 4 hours compared to 16% when receiving placebo, with a numbers needed to treat (NNT) of 4.0 (3.5-4.8) for benefit. At 6 hours, 26% of patients receiving paracetamol or propacetamol still experienced 50% pain relief, with a NNT of 5.3 (4.2-6.7). Furthermore, patients receiving paracetamol demonstrated 30% reduction in opioid consumption during 0-4 hours and 16% reduction in opioid consumption during 0-6 hours of postoperative period compared with patients receiving placebo \[[@B45]\].

The utility of acetaminophen for postoperative pain control and opioid-sparing has also been studied in pediatric patients. A systematic review aimed to assess the opioid-sparing effect of NSAIDs and acetaminophen reported that 7 of 13 (54%) treatment arms which received acetaminophen yield significant postoperative opioid-sparing \[[@B46]\]. However, the drug delivery route in most studies were rectal, and only 2 studies by a same group of researchers used intravenous acetaminophen, as a single agent with opioid or in combination with ketorolac, which both reported significant fentanyl sparing \[[@B47],[@B48]\]. A recent randomized controlled trial compared the efficacy and morphine sparing effect of intravenous acetaminophen given as a primary analgesic after major abdominal or thoracic surgery in neonates and infants under 1 year of age \[[@B49]\]. In this study, compared with morphine (control) group, the cumulative morphine dose was 66% decreased in the acetaminophen group, but the total morphine rescue dose between the two groups did not vary significantly, indicating a similar efficacy for analgesia in either groups. This study provided important documentation that intravenous acetaminophen can be a potential alternative to opioids as a primary analgesic agent for postoperative pain control in neonates and young infants \[[@B49]\].

Although many articles reviewed the efficacy of intravenous acetaminophen for postoperative pain control and opioid reduction, there were few studies reporting the effect of acetaminophen for reducing opioid related adverse effects in the postoperative period. A systematic review of intravenous acetaminophen for the effect in nausea and vomiting after general anesthesia has been recently published \[[@B16]\]. This meta-analysis analyzed 30 studies involving 2,364 patients, of whom 1,223 were in the acetaminophen group and 1,141 were in the placebo group. Intravenous acetaminophen was associated with a relative risk for postoperative nausea of 0.73 and 0.63 for vomiting, indicating a decrease in postoperative nausea and vomiting (PONV). The timing of intravenous acetaminophen administration was important: most effective when given before and during the surgery and less when given after surgery after the onset of postoperative pain. However, the reduction of PONV was related to a the decrement in postoperative pain and not associated with postoperative opioid consumption, indicating that pain itself maybe an important risk factor for PONV \[[@B16]\].

Intravenous acetaminophen is known to be safe and well tolerated, sharing similar safety profiles of the rectal and oral formulations, with an adverse event profile similar to placebo \[[@B50],[@B51],[@B52]\]. Significant adverse reactions associated with intravenous acetaminophen are extremely rare, occurring at an approximate incidence of fewer than 1/10,000 \[[@B43]\]. Typically reported adverse events include hypotension, malaise, hypersensitivity reaction, liver enzyme elevation, and thrombocytopenia \[[@B43]\]. The most well-known safety concern with the use of acetaminophen is the potential hepatotoxicity when used above recommended doses (\> 4 g/day for adults over 50 kg). To evaluate the safety of intravenous acetaminophen, a randomized double-blinded placebo-controlled study was conducted, showing no significant difference in the treatment-emergent adverse event (TEAE) between the placebo group (N = 110) and the intravenous acetaminophen group (N = 134), and only 1 patient in the placebo group showed an increase in hepatic aminotransferase \[[@B53]\]. In another open label prospective study involving 213 patients, intravenous acetaminophen was administered in different doses (650 mg q 4 hr: N = 91, 1,000 mg q 6 hr: N = 92) in an \"around-the-clock\" regimen for 5 days compared to the control group, which was standard-of-care (N = 30). Typical medications considered appropriate for the treatment of fever or pain were administered in the standard-of-care treatment arm. The prevalence of hepatic TEAEs considered to be correlated with acetaminophen was low and minor, with no major hepatic issues related to intravenous acetaminophen administration \[[@B54]\]. The depleted glutathione storage does not appear to be an increased risk factor for patients with severe hepatic disease and are at an increased risk for hepatotoxicity; therapeutic doses of acetaminophen are unlikely to precipitate severe hepatic TEAEs \[[@B55],[@B56]\].

Intravenous Ibuprofen
=====================

Ibuprofen is a propionic acid derivative, sharing the anti-inflammatory, antipyretic and analgesic effects which most other NSAIDs have. It was developed by the Boots group of United Kingdom in the 1960s \[[@B57]\]. The oral form has been marketed in 1969 in the United Kingdom and in 1974 in the United States. Since its approval in the United States and United Kingdom, ibuprofen has been primarily used as an over-the-counter (OTC) drug, making it one of the most frequently used oral NSAID. Also in Korea, it has been approved for OTC supply and is available to purchase this drug without prescriptions. The intravenous form of ibuprofen (Caldolor®) has been approved for the treatment of mild to moderate pain, and for the treatment of moderate to severe pain as augmentation to opioids in the United States at June 2009 \[[@B58],[@B59]\]. Recently, intravenous ibuprofen has been approved in Korea for the treatment of pain and fever and is available. Before the approval of intravenous ibuprofen, ketorolac was the only intravenous NSAID in the United States.

The analgesic effect of ibuprofen is related to inhibition of the cyclooxygenase isoenzymes. Administration of ibuprofen causes a rapid, reversible and competitive inhibition of COX-1 and COX-2 enzymes, preventing the production of prostaglandins \[[@B60],[@B61]\]. Like majority of other NSAIDs, ibuprofen\'s analgesic, antipyretic, and anti-inflammatory activities appear to operate mainly through inhibition of the COX-2 isoenzyme, whereas inhibition of COX-1 is responsible for the unwanted side effects (mainly on the gastrointestinal tract and kidney) \[[@B61]\].

The selectivity of individual NSAIDs to COX-1 and COX-2 are closely related to the probability of unwanted adverse effects. A drug that has a ratio of COX-1 : COX-2 inhibition greater than 1 is likely to be associated with adverse events than those with COX-1 : COX-2 inhibition ratio less than 1 \[[@B62],[@B63]\]. Oral ibuprofen 2,400 mg/day demonstrated inhibition of COX-1 activity by 88.7% and COX-2 activity by 71.4% in a healthy volunteer study \[[@B64]\]. The relative ratio of COX-1 : COX-2 inhibition of NSAIDs are summarized in [Fig. 2](#F2){ref-type="fig"} \[[@B65]\]. Ibuprofen inhibits COX-1 2.5 times more than COX-2, where as ketorolac inhibits COX-1 over 300 times more than COX-2 in humans.

As with many other NSAIDs, ibuprofen is composed of a racemic mixture of S- and R-isomers. While the R-enantiomer is pharmacologically inactive in vivo and in vitro, the S-enantiomer has proven to be the etiology of the clinical activity of ibuprofen. However, the R-enantiomer is slowly and incompletely (approximately 60%) converted to the active S-enantiomer in adult plasma, thereby acting as a reservoir for maintenance of the circulating concentration of ibuprofen. For the treatment of pain in adults, the recommended dose of intravenous ibuprofen is 400 to 800 mg every 6 hours. For fever, 400 mg is initially infused and 400 mg every 4 to 6 hours or 100 to 200 mg every 4 hours as required. The infusion time must be at a minimum of thirty minutes. Before infusion, intravenous ibuprofen should be diluted to a final concentration of 4 mg/ml or less, resulting in a final solution of no less than 100 ml (400 mg) or 200 ml (800 mg). Intravenous ibuprofen has been formulated in 400 mg (4 ml) and 800 mg (8 ml) dosages; the 400 mg packaged dose is available in Korea.

The pharmacokinetic properties of intravenous ibuprofen were studied compared to healthy adult volunteers and febrile hospitalized patients. Febrile patients were further stratified to critically ill or not. In the study of febrile patients, 120 adult subjects were enrolled and received a placebo or 100 mg, 200 mg, 400 mg intravenous ibuprofen \[[@B66]\]. The area under the curve for plasma concentration-time from 0 hour to 4 hours (AUC~0-4~) after initial administration of the drug, was determined in this study. The AUC~0-4~ was determined to be proportional for the 200 mg and 400 mg levels of ibuprofen in this study. Furthermore, compared with the non-critically ill population, the plasma concentration of ibuprofen in all administered doses was significantly decreased in the critically ill population \[[@B66]\]. In the healthy adult volunteer study, which was a single dose placebo-controlled crossover trial, 12 healthy adult were enrolled to receive single intravenous dose of ibuprofen or placebo, and oral administration of ibuprofen or placebo (800 mg). First, intravenous ibuprofen was compared with oral ibuprofen. The pharmacokinetic parameters were observed to be similar in either route of administration, except intravenous infusion of ibuprofen demonstrated higher C~max~, and faster T~max~ compared with oral administration \[[@B67]\]. Second, rapid intravenous infusion of 800 mg ibuprofen within 5-7 minutes were compared with oral 800 mg administration and further compared with historical or modeled data of intravenous ibuprofen of 400 mg and 800 mg, slowly infused over 30 or 60 minutes. The rapid infusion of ibuprofen 800 mg (5-7 minutes) and the modeled data of 5-7 minute infusion of ibuprofen 400mg showed to have significantly increased C~max~ values and shorter T~max~ values compared with 30 or 60 minute infusion of the same dose of ibuprofen \[[@B58]\] ([Table 2](#T2){ref-type="table"}).

To analyze the therapeutic efficacy of intravenous ibuprofen for the management of postoperative pain in adult patients who underwent orthopedic or abdominal surgery, three randomized double blinded placebo controlled trials were conducted. In two studies, at the start of wound closure in patients who underwent orthopedic or abdominal surgery, intravenous ibuprofen was initially administered intraoperatively \[[@B68],[@B69]\]. Total of 319 patients and 406 patients were enrolled in each study and randomized to receive 400 mg or 800 mg of intravenous ibuprofen or placebo every 6 hours for up to 120 hours \[[@B68]\], and 800 mg of intravenous ibuprofen or placebo every 6 hours for 24 hour postoperative period \[[@B69]\]. In both studies, during the first 24 hours after operation, the administration of 800 mg of intravenous ibuprofen resulted in a significant decrease in median morphine administered during the first 24 hours after operation (22 and 19%) compared with placebo. Compared with placebo both doses of intravenous ibuprofen administered every 6 hours resulted in a significant decrease in pain scores at rest and movement during the first 24 hours. In another randomized trial, placebo or intravenous ibuprofen 800 mg was initially administered preoperatively in 185 adult orthopedic patients, considering the effect of ibuprofen in preemptive analgesia \[[@B70]\]. In this study, patients received four more scheduled doses of placebo or 800 mg ibuprofen every 6 hours, and after 24 hours, further administration was delivered as needed to a maximum of 120 hours. There was a significant reduction in mean pain score at movement and rest compared with placebo during the first 6 to 28 postoperative hours. Compared with placebo, a significant decrease in mean morphine consumption (30.9%) was observed in the ibuprofen group. Compared with placebo group, there was also a substantial reduction in immediate postoperative pain in the ibuprofen group demonstrating the possible preemptive analgesic effect of preoperatively administered ibuprofen \[[@B70]\]. In all three studies, there was no significant variance in the overall incidence of TEAE, including severe adverse events, and the daily dose of ibuprofen 3,200 mg was well tolerated \[[@B68],[@B69],[@B70]\]. Further studies are underway, including the effect of intravenous ibuprofen for the treatment of myalgias after electroconvulsive therapy, acute migraine exacerbation, inguinal hernia repair and pediatric patients \[[@B59]\].

Intravenous ibuprofen was commonly well tolerated by patients in the multiple clinical trials evaluating the efficacy of intravenous ibuprofen for pain and fever treatment \[[@B66],[@B68],[@B69],[@B70],[@B71],[@B72]\]. Furthermore, no significant variance was witnessed in the outcome of 455 patients who received either intravenous ibuprofen or placebo for the treatment of sepsis \[[@B73]\]. The most common TEAE following intravenous ibuprofen treatment in postoperative pain trials was nausea, flatulence, hemorrhage, vomiting, headache, dizziness and urinary retention. The most common TEAE following intravenous ibuprofen for the treatment in fever was anemia and eosinophilia \[[@B59]\]. Other possible adverse effect of ibuprofen is similar with other NSAIDs. It may elevate the risk of cardiovascular thrombotic events, gastrointestinal adverse events consisting of gastrointestinal bleeding and ulceration, increase in liver enzyme, onset or worsening of hypertension, fluid retention and serious skin adverse events. Ibuprofen is contraindicated in patients with asthma, allergic reactions to aspirin and other NSAIDs and patients undergoing coronary artery interventions or coronary artery bypass surgery. Ibuprofen should be utilized in caution for patients with a history of gastrointestinal bleeding or ulcer, hepatic and renal diseases, hypertension, heart failure and elderly patients \[[@B59]\]. If significant bleeding is expected or risk of bleeding after surgery is possible, the administration of pre- or perioperative ibuprofen should be reconsidered, as oral ibuprofen is known to dose proportionally significantly inhibit the activity of thromboxane B2, platelet aggregation and prolong bleeding time compared with placebo \[[@B64],[@B74]\].

Summary
=======

Based on the scientific reviews of both intravenous acetaminophen and ibuprofen, it should be clear that both are safe and effective if used as directed, and improve pain and satisfaction scores. Additionally, they decrease opioid use and likely contribute to fewer adverse events, due to this, or possibly as they may have fewer adverse events when administered intravenously (lack of first pass effect, controlled administration where known dosing regimens are employed, and increased vigilance in a hospital or clinic setting compared to home use/overuse).

Preemptive use of both agents appears to convey even greater relief or prevention of pain, although confirmatory studies would be helpful in large cohorts of diverse patients. Also, long term outcome with use of the intravenous agents is lacking, and perhaps provides improvements, although distinguishing between intravenous and other formulations over time would be challenging.

In conclusion, intravenous acetaminophen and ibuprofen are important options either alone or in combination, for management of pain and fever, and reductions in opioid use, validating the World Health Organization\'s pain ladder \[[@B13]\], with use of these medications and regional anesthesia as the first line in the mitigation of acute pain.

![The ladder of therapy for multimodal postoperative pain management. The figure is adapted from \[[@B13]\].](kjae-68-3-g001){#F1}
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###### 

Main Pharmacokinetic Parameters of Acetaminophen following Intravenous Administration of 5 g during the First 24 hr with a 2 g Starting Dose

![](kjae-68-3-i001)

The table is adapted from \[51 *sic*\] with permission for reuse. C~max~: maximum observed concentration, T~max~: time to reach C~max~, C~min~: minimum concentration observed within a dosing interval, T1/2γ: terminal half-life, AUC~0-τ~: area under the concentration-time curve during a dosing interval. ^\*^Median (min - max).

###### 

Main Pharmacokinetic Parameters of Ibuprofen following Intravenous Single Dose Administration of 800 mg or 400 mg Infused over 5-7, 30 or 60 Minutes Compared with a Single Same Oral Dose
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The table is adapted from \[58 *sic*\] with permission for reuse. IV: intravenous, min: minute, hr: hour, C~max~: maximum observed concentration, T~max~: time to reach C~max~, T~1/2~: elimination half-life. ^\*^Modeled data.
